Harrow Health, Inc. (NASDAQ: HROW) owns a portfolio of healthcare businesses, including the nationâs leading ophthalmology pharmaceutical compounding business, ImprimisRx. The company holds large equity positions in Eton Pharmaceuticals, Surface Pharmaceuticals, Melt Pharmaceuticals, Mayfield Pharmaceuticals and Radley Pharmaceuticals, companies founded as subsidiaries of Harrow Health. The Company also owns royalty rights in certain 505(b)(2) drug candidates being developed by Eton, Surface, Melt, Mayfield and Radley. Harrow intends to create, invest in and grow paradigm shifting health care businesses that put patients first. Source
No articles found.
TherapeuticsMD, Inc. is an innovative pharmaceutical company exclusively committed...
TherapeuticsMD, Inc. is an innovative pharmaceu...
H&G Science aims to facilitate the safe and effective treatment of diseases. Our g...
H&G Science aims to facilitate the safe and eff...
Neos Therapeutics develops, manufactures, and commercializes innovative extended-r...
Neos Therapeutics develops, manufactures, and c...
Liquidia is a late-stage clinical biopharmaceutical company focused on the develop...
Liquidia is a late-stage clinical biopharmaceut...
Spark Therapeutics, a fully integrated company, strives to challenge the inevitabi...
Spark Therapeutics, a fully integrated company,...
Join the National Investor Network and get the latest information with your interests in mind.